Paul Kayne PhD, BA

Paul currently heads the Genomics Technologies group at Bristol-Myers Squibb and is involved in the identification, evaluation, and deployment of new gene expression technologies. Previously, he was based at GSK where he developed microarrays for high throughput expression profiling